Company: Sonus Pharmaceutical [1]
Starting stock price: $6.02
Ending stock price: $0.44
Percent Change: -92.69%
Details: Sonus was delivered a crushing blow in September. A Phase III study of the company's breast cancer therapy, Tocosol Paclitaxel, was found to be less effective and linked to more side effects than Taxol. Bayer Schering terminated it's partnership with Sonus on the drug in October. The company has since enlisted Ferghana Partners to help evaluate the company's "alternative strategies." Sonus has one other cancer drug in development.
Related Articles:
Sonus shares shattered on drug failure. Report [2]
Sonus shares surge as FDA approves Phase III design. Report [3]
Links:
[1] http://www.sonuspharma.com/
[2] http://www.fiercebiotech.com/story/sonus-shares-shattered-drug-failure/2007-09-24?utm_medium=rss&utm_source=rss
[3] http://www.fiercebiotech.com/story/sonus-shares-surge-as-fda-approves-phase-iii-design/2005-07-08
[4] http://www.fiercepharma.com/special-reports/worst-pharma-stocks-2007
[5] http://www.fiercepharma.com/special-reports/threshold-pharmaceuticals-worst-pharmastocks-2007